DARK ADAPTATION IN MACULAR TELANGIECTASIA TYPE 2

Retina. 2020 Oct;40(10):2018-2025. doi: 10.1097/IAE.0000000000002694.

Abstract

Purpose: To evaluate dark adaptation (DA) in patients with macular telangiectasia Type 2 (MacTel).

Methods: After a local photobleach (4 × 4° size, 83% bleach), DA was measured using a test stimulus (2° diameter) projected at 5° eccentricity horizontal from the foveal center within the temporal parafovea. Cone plateau, rod intercept time, and rod recovery rate (S2) were calculated from the resulting DA curves. Findings were correlated with disease stages (according to Gass and Blodi), the area of ellipsoid zone loss in optical coherence tomography, and macular pigment loss ("MP-Classes 1-3").

Results: Fifty-nine eyes of 59 patients were compared with 18 eyes of 18 healthy controls. Dark adaptation was significantly impaired in patients with MacTel. Although differences were most pronounced for parameters indicating rod-mediated recovery, cone-mediated recovery was also decreased, yet to a lesser extent. Dark adaptation parameters were only weakly associated with disease stages and ellipsoid zone loss. A better association was found between rod-mediated recovery (S2 and rod intercept time) and macular pigment loss (Kendall's tau for rod intercept time: 0.69 and S2: -0.51; both P < 0.0001).

Conclusion: Dark adaptation is significantly impaired in patients with MacTel. Our results indicate an association of reduced macular pigment and rod dysfunction in MacTel.

MeSH terms

  • Aged
  • Cross-Sectional Studies
  • Dark Adaptation / physiology*
  • Female
  • Humans
  • Macular Pigment / metabolism
  • Male
  • Middle Aged
  • Prospective Studies
  • Retinal Cone Photoreceptor Cells / physiology
  • Retinal Rod Photoreceptor Cells / physiology
  • Telangiectasia, Hereditary Hemorrhagic / diagnostic imaging
  • Telangiectasia, Hereditary Hemorrhagic / physiopathology*
  • Tomography, Optical Coherence
  • Visual Acuity / physiology

Substances

  • Macular Pigment

Supplementary concepts

  • Osler-rendu-weber syndrome 2